Tags

Type your tag names separated by a space and hit enter

[Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer].
Zhonghua Wai Ke Za Zhi. 2003 May; 41(5):332-5.ZW

Abstract

OBJECTIVE

To confirm the effect of combined detection of K-ras gene mutation and CA 19-9 level in plasma in the diagnosis of pancreatic carcinoma.

METHODS

In 33 patients without pancreatic carcinoma and 15 patients with pancreatic carcinoma, the value of K-ras mutation and CA 19-9 level were examined by enriched polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and radioimmunoassay respectively. The data were analysed with chi(2) test, Fisher's exact test and Kruekal-wall's test. All patients were confirmed pathologically.

RESULTS

Eleven of the 15 patients with pancreatic carcinoma and 2 of 10 patients with chronic pancreatitis were found K-ras mutation. CA 19-9 level in patients with pancreatic cancer was significantly higher than that in those with benign disease but with a low specificity. The sensitivity, specificity of combined detection of K-ras gene mutation and CA 19-9 level in the plasma of patients with pancreatic cancer were 66.67% and 97%. There was a significant difference between patients with pancreatic cancer and those without pancreatic cancer. Pathological examination showed atypical hyperplasia in one patient with chronic pancreatitis who had K-ras mutation and higher CA 19-9 level.

CONCLUSIONS

Combined detection of K-ras gene mutation and CA 19-9 can be used for adjuvant diagnosis of pancreatic cancer. It is more specific than detection of single K-ras gene mutation or CA 19-9 level in the plasma. The method is complementary to single detection of K-ras gene mutation or CA 19-9 level because it decreases the rate of false-positive diagnosis.

Authors+Show Affiliations

Department of General Surgery. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

chi

PubMed ID

12892584

Citation

Dai, Meng-hua, et al. "[Combined Detection of K-ras Mutation and CA 19-9 Level in Plasma of Patients With Pancreatic Cancer]." Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery], vol. 41, no. 5, 2003, pp. 332-5.
Dai MH, Zhao YP, Cai LX, et al. [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer]. Zhonghua Wai Ke Za Zhi. 2003;41(5):332-5.
Dai, M. H., Zhao, Y. P., Cai, L. X., & Zhu, Y. (2003). [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer]. Zhonghua Wai Ke Za Zhi [Chinese Journal of Surgery], 41(5), 332-5.
Dai MH, et al. [Combined Detection of K-ras Mutation and CA 19-9 Level in Plasma of Patients With Pancreatic Cancer]. Zhonghua Wai Ke Za Zhi. 2003;41(5):332-5. PubMed PMID: 12892584.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Combined detection of K-ras mutation and CA 19-9 level in plasma of patients with pancreatic cancer]. AU - Dai,Meng-hua, AU - Zhao,Yu-pei, AU - Cai,Li-xing, AU - Zhu,Yu, PY - 2003/8/2/pubmed PY - 2008/12/23/medline PY - 2003/8/2/entrez SP - 332 EP - 5 JF - Zhonghua wai ke za zhi [Chinese journal of surgery] JO - Zhonghua Wai Ke Za Zhi VL - 41 IS - 5 N2 - OBJECTIVE: To confirm the effect of combined detection of K-ras gene mutation and CA 19-9 level in plasma in the diagnosis of pancreatic carcinoma. METHODS: In 33 patients without pancreatic carcinoma and 15 patients with pancreatic carcinoma, the value of K-ras mutation and CA 19-9 level were examined by enriched polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) and radioimmunoassay respectively. The data were analysed with chi(2) test, Fisher's exact test and Kruekal-wall's test. All patients were confirmed pathologically. RESULTS: Eleven of the 15 patients with pancreatic carcinoma and 2 of 10 patients with chronic pancreatitis were found K-ras mutation. CA 19-9 level in patients with pancreatic cancer was significantly higher than that in those with benign disease but with a low specificity. The sensitivity, specificity of combined detection of K-ras gene mutation and CA 19-9 level in the plasma of patients with pancreatic cancer were 66.67% and 97%. There was a significant difference between patients with pancreatic cancer and those without pancreatic cancer. Pathological examination showed atypical hyperplasia in one patient with chronic pancreatitis who had K-ras mutation and higher CA 19-9 level. CONCLUSIONS: Combined detection of K-ras gene mutation and CA 19-9 can be used for adjuvant diagnosis of pancreatic cancer. It is more specific than detection of single K-ras gene mutation or CA 19-9 level in the plasma. The method is complementary to single detection of K-ras gene mutation or CA 19-9 level because it decreases the rate of false-positive diagnosis. SN - 0529-5815 UR - https://www.unboundmedicine.com/medline/citation/12892584/[Combined_detection_of_K_ras_mutation_and_CA_19_9_level_in_plasma_of_patients_with_pancreatic_cancer]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0529-5815&year=2003&vol=41&issue=5&fpage=332 DB - PRIME DP - Unbound Medicine ER -